GlaxoSmithKline eyes €2.5B bond sale; Japanese tax rollback may trigger drug price cuts;

@FiercePharma: Merck KGaA to power India plant with coconut and cashew shells. Story | Follow @FiercePharma

@CarlyHFierce: AstraZeneca's Almirall buy yields its first new drug--and now, AZ has to sell it. More | Follow @CarlyHFierce

> GlaxoSmithKline ($GSK) is planning its first euro bond sales since 2009, thanks to ultralow borrowing costs in the currency. Report

> Japanese Prime Minister Shinzō Abe's decision to postpone a sales-tax hike may trigger annual drug price cuts, rather than the current biennial decisions. Report

> The Cubist Pharmaceuticals ($CBST) antibiotic Dificlir proved to be cost-effective in treating patients with Clostridium difficile infection, compared with the standard of care, according to a study. Report

> Eisai rolled out its breast cancer treatment Halaven in Brazil. Report

Medical Device News

@FierceMedDev: Congress considering bill to limit FDA regulation of EHRs, clinical decision support software. Story | Follow @FierceMedDev

@VarunSaxena2: RT @FierceMedDev: From FierceDrugDelivery: Survey raises the question: Do patients really know how to use drug delivery devices? Story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI: LabCorp and CareDx call it quits on partnership to develop lupus test. FierceDiagnostics story | Follow @EmilyWFierce

> Opponents of FDA's LDT regulations lawyer up, get in combat mode. Story

> WSJ: Ankle replacements look to be the next thing. More

> Strategic investors LabCorp, Envision put $15M into remote patient monitoring startup Vivify. Article

Biotech News

@FierceBiotech: Woodford's investment strategy may help change the global biotech scene. Editor's Corner | Follow @FierceBiotech

@JohnCFierce: Fledgling biotech upstart blends cutting-edge cancer immunotherapy strategies -- BeneVir. Article | Follow @JohnCFierce

@DamianFierce: It's almost as if Italian authorities don't care about biotech traders. More | Follow @DamianFierce

> Amgen, AstraZeneca's brodalumab beats J&J's Stelara in 2nd PhIII psoriasis showdown. News

> Biotech's Boston blitz is making lab space harder--and costlier--to come by. Story

> Novartis cans a researcher whose cooked data led to a slew of retractions. More

Drug Delivery News

> RNAi specialist Arrowhead reports loss of $58.7M in FY 2014. Item

> Singapore team combines cancer drugs, diagnostics in one biomarker nanoparticle. Report

> 'Hybrid' delivery vehicle gives DNA vaccines new potential. News

> Survey raises the question: Do patients really know how to use drug delivery devices? More

> Patients respond positively to Cynapsus film strip of apomorphine to combat Parkinson's. Article

Diagnostics News

> Curetis nabs $18M to support European Dx rollout, U.S. trial, possible IPO. News

> Illumina and bioMérieux to develop innovative sequencing system for infectious diseases. Article

> Indian startup develops low-cost, portable Dx for developing countries. Story

> LabCorp and CareDx call it quits on partnership to develop lupus test. Report

> Illumina teams up with Broad Institute, USAID for Ebola tracking. Item

Pharma Marketing News

> Who are the stars of personalized medicine? Roche, Novartis and J&J. Article

> From GPS inhalers to Jawbone data-gathering, some digital pharma inspiration. Story

> MannKind fans and critics line up for Sanofi's Afrezza pre-game show. More

> Ipsen on a hiring binge in U.S. to prep for new Somatuline marketing push. Story

> AstraZeneca's Almirall buy yields its first new drug--and now, AZ has to sell it. Article

And Finally... Almost one-quarter of cancer cases in the U.S. are linked to obesity, a World Health Organization report says. Report

Suggested Articles

Pfizer will exit its Perth, Australia sterile injectables manufacturing site by 2024 as part of a global production reorganization effort.

Agios has withdrawn a European application for Tibsovo in AML after the same phase 1 data that earned it an FDA nod failed to impress the EMA.

Sanofi is reportedly considering a sale of some of its anti-inflammation drugs that could snare $234 million as the company pivots toward Dupixent.